CureVac reports Q3 revenue EUR 54.1M vs. EUR 493.9M last year

“This quarter, we have made continued progress toward completing the planned transaction with BioNTech, bringing us closer to realizing our shared vision of bringing together two pioneers in mRNA science with complementary capabilities and technologies,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac (CVAC). “Together, we aim to accelerate the development of innovative and transformative mRNA-based therapies for patients in need.”